- Home
- NG vs NRIX Comparison
NG vs NRIX Comparison
Compare NG & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NG | NRIX |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NG | NRIX |
|---|---|---|
| Price | $9.98 | $17.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $10.17 | ★ $27.46 |
| AVG Volume (30 Days) | ★ 2.5M | 1.8M |
| Earning Date | 01-22-2026 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,687,000.00 |
| Revenue This Year | N/A | $59.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.32 |
| 52 Week Low | $2.26 | $8.18 |
| 52 Week High | $10.90 | $22.50 |
Technical Indicators
Market Signals| Indicator | NG | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 56.62 | 45.83 |
| Support Level | $8.92 | $18.78 |
| Resistance Level | $10.10 | $19.54 |
| Average True Range (ATR) | 0.40 | 0.86 |
| MACD | -0.06 | -0.41 |
| Stochastic Oscillator | 70.41 | 10.77 |
Price Performance
Historical ComparisonAbout NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.